Key result
Mortality risk associated with ACE-inhibitor treatment in hypertensive patients increased with the number of D alleles, reaching RR 1.61 (95% CI 1.18-2.18) for total mortality in the DD genotype group.
Why the study?
Does ACE-inhibitor therapy interact with the ACE I/D polymorphism to affect incident heart failure and mortality in hypertensive patients?
Cohort (n=3,365)
Does ACE-inhibitor therapy interact with the ACE I/D polymorphism to affect incident heart failure and mortality in hypertensive patients?
Effect estimate: RR 1.61 (95% CI 1.18-2.18)
The ACE I/D polymorphism modifies the mortality risk associated with ACE-inhibitor therapy in hypertensive patients, with the DD genotype showing relative resistance and increased mortality risk compared to the II genotype.
No takes yet. Share an insight, caveat, or question.
ACE I/D genotyping should not guide ACE-inhibitor prescribing in hypertension; hypothesis-generating for pharmacogenetic mortality effects in prospective trials.
Bleumink et al. (2005) conducted a cohort in Hypertension (n=3,365). ACE-inhibitors vs. Non-use of ACE-inhibitors across different ACE I/D genotypes was evaluated on Total mortality (RR 1.61, 95% CI 1.18-2.18). Mortality risk associated with ACE-inhibitor treatment in hypertensive patients increased with the number of D alleles, reaching RR 1.61 (95% CI 1.18-2.18) for total mortality in the DD genotype group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: